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Abstract 
Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25-30% in 
unselected populations and has become the main reason for referrals to 
hepatology services. From a liver point of view, NAFLD is a disease of high 
prevalence but relatively low severity. Screening studies in people at risk show a 
prevalence of advanced fibrosis of 5%, which underlines the need for robust 
pathways for risk stratification in primary care with subsequent referrals as 
required. In this review, we discuss the interface between primary and 
secondary care with regard to risk stratification and management of patients 
with NAFLD. We focus on selected issues of epidemiology and natural history 
and discuss the burden of disease in primary care, the evidence on screening for 
NAFLD, the rationale for testing for advanced fibrosis and the optimal 
management in primary care. 
  
Introduction 
Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25-30% in the 
general population and has thus become the main reason for referrals to 
hepatology services1,2. The number of patients diagnosed and referred is 
projected to rise further secondary to the growing epidemic of obesity and 
diabetes but also the increasing awareness of the disease.  
 
NAFLD is a systemic disease and is often perceived as an inconsequential hepatic 
manifestation of the metabolic syndrome; although some patients will develop 
progressive liver disease that can lead to cirrhosis and liver cancer, the majority 
of those affected will never develop hepatic complications. Indeed, 
cardiovascular disease is the main cause of mortality in patients with NAFLD 
followed by non-liver related malignancies3. Therefore, from a liver point of 
view, NAFLD is a disease of high prevalence but relatively low severity. It is 
therefore critical that primary care physicians are actively involved in the 
screening and management of patients, with community pathways in place for 
selecting patients at risk of liver disease for secondary care referral and 
adequate education for following up and treating those deemed at low risk. In 
this review, we discuss the interface between primary and secondary care as 
regards risk stratification and management of patients with NAFLD. We focus on 
selected issues of epidemiology and natural history and discuss the burden of 
disease in primary care, the evidence on screening for NAFLD, the rationale for 
testing for advanced fibrosis and the optimal management in primary care. This 
review is relevant for primary care and/or other specialties that make the first 
diagnosis of NAFLD or treat the majority of people at risk of NAFLD. Parts of the 
manuscript on screening and testing are also relevant for secondary care 
clinicians developing services for NAFLD and for commissioners of those 
services. We further highlight areas of uncertainty and needs for future research. 
 
 
Search strategy and selection criteria 
We searched MEDLINE (2005-2017) using the search term "NAFLD" or “NASH” 
combined with the terms “non-invasive fibrosis tests” or “primary care” or 
“prevalence” or “incidence” or “treatment”. Articles were also selected through 
searches of the authors’ own files. We selected further relevant publications 
from the reference lists of articles identified by this search strategy. We largely 
selected publications in the past 5 years, but did not exclude highly relevant 
older publications. Review articles are cited to provide more details and 
references than this Seminar has room for.  
 
Epidemiology 
NAFLD is an increasingly common global entity which is defined by the presence 
of hepatic steatosis and varying degrees of liver injury and fibrosis, occurring in 
the absence of any other aetiological factors notably alcohol excess4. Its 
emergence over the past 20 years has been driven by the dramatic rise in levels 
of obesity and type 2 diabetes mellitus with which it is closely linked5.  
 
Population and other studies have used different methods to diagnose NAFLD, 
which in turn has a major impact on the prevalence figures generated; in general 
studies requiring abnormal liver blood tests to make the diagnosis of NAFLD 
generate much lower figures compared to those utilising imaging modalities. The 
observation that patients with NAFLD, and indeed those with significant liver 
damage, may have entirely normal liver blood tests is widely accepted but has 
impacted on case-finding in clinical practice6. In addition, NAFLD refers to 
patients with the full spectrum of the condition, ranging from indolent steatosis 
through to progressive inflammation, non-alcoholic steatohepatitis (NASH), and 
fibrosis culminating in cirrhosis7. As the distinction often requires recourse to 
additional investigations, some invasive such as liver biopsy, there are more 
limited data on the prevalence of NASH and progressive fibrosis. This is relevant 
as there is a growing recognition that complications related to liver disease arise 
only after many years and predominantly in those individuals with NASH and 
fibrosis. 
 
The global data on prevalence of NAFLD and NASH have been reviewed recently 
by Younossi et al8; 86 studies from 22 countries included 8,515,431 patients and 
established a global prevalence of 25.24% (95% CI: 22.10-28.65) with the 
highest prevalence found in the Middle East and South America. Nevertheless, 
there were broadly similar prevalence figures across the different geographical 
regions, with prevalence plateauing after the age of 40 before rising further 
beyond the age of 70. Pooled overall prevalence estimate in those patients with 
NAFLD being 59.10% (95% CI: 47.55-69.73), but extrapolating this to the 
population prevalence of NASH is more difficult given the inherent biases in such 
figures, which are commonly generated in specialist centres. Modeling data, 
again from Younossi and colleagues, suggests a prevalence of 2-5% of NASH 
across the US and major European countries8. 
 Finally data on the prevalence of NASH with advanced fibrosis are even sparser 
yet of greater clinical importance. Population based studies report lower 
prevalence figures than those from specialist centres highlighting ascertainment 
bias in the latter. Nonetheless these figures conservatively suggest a prevalence 




There is an uncertain understanding of the progression of liver damage in the 
setting of NAFLD/NASH; in the main this is due to the reliance on liver biopsy to 
track changes in liver injury. Moreover, most of the datasets reported are single 
centre studies from specialist units where repeat biopsy occurred in response to 
clinical events – inevitably this results in a bias as repeat biopsy will be driven by 
clinical concerns in many patients providing a non-representative understanding 
of the overall rate of change. When analysed, Singh and colleagues, determined 
that rate of histological progression differed depending on severity of baseline 
NAFLD9; those with more indolent disease at the outset appeared to progress 
more slowly, whereas those with NASH progressed more rapidly. These data are 
helpful in informing the field but it should be noted though that the rates of 
progression were still slow; the time taken to advance by one stage of liver 
fibrosis was 7 years in `fast` progressors versus 14 years in `slow` progressors9.  
 
A relevant consideration is the method of evaluating changes in fibrosis in 
patients with NASH. This uses the established NASH Clinical Research Network 
(CRN) classification which stages fibrosis from 0 to 4 depending on the 
histological pattern observed7. This system whilst useful has some limitations; 
the fibrosis is graded categorically yet analysed as if it was a continuous variable. 
Moreover, the staging system is not linear with absolute differences in fibrosis 
between the earliest stages being modest whereas later stages have more 
marked increases in collagen. This is relevant as in the systematic review by 
Singh most patients had fibrosis within the earliest categories of fibrosis and 
hence the reported changes in stage represent relatively small changes in 
fibrosis9. Of note these studies also demonstrate that there is a significant 
amount of spontaneous improvement in fibrosis seen at these early stages in 
NASH highlighting the dynamic nature of disease. 
To understand which factors predicted histological change Singh and colleagues 
undertook logistic regression followed by a multi-variate analysis. A number of 
features were observed as predicting progression at univariate analysis, 
although notably only hypertension remained as a predictive factor after 
multivariate analysis9. This could represent a chance finding, although there may 
be logic in the link between activation of the renin angiotensin axis and ongoing 
liver fibrogenesis, as highlighted by the potential beneficial role of angiotensin 
converting enzyme inhibition in liver fibrosis10.  
 
Whilst there is an understandable focus on liver morbidity and mortality in 
patients with NASH, analysis of outcomes in such cohorts demonstrates that 
deaths from cardiovascular disease and non-liver malignancy are the top two 
causes11,12. Given the co-existence of often multiple metabolic syndrome factors 
in patients with NASH this is not surprising. This knowledge is of particular 
relevance for the shared management of such patients in primary care where 
there should be a clear focus on the optimal management of the metabolic 
syndrome. Identification of the factors predicting the development of overall and 
liver-related mortality has been the focus of many recent studies, with the 
finding that metabolic factors such as diabetes mellitus and HMG co-A reductase 
usage are important prognostic factors. Similarly the presence and severity of 
liver fibrosis has been reported in several studies to be a strong predictor of 
overall and liver-related mortality. The link with liver-related mortality is to be 
expected, and the data by Dulai et al suggest that the risk manifests after the 
development of more significant liver fibrosis (F2) and rises exponentially 
thereafter13. The link with overall mortality pertains at even lower levels of 
fibrosis and rises in a more proportionate fashion with fibrosis. This could 
represent a surrogate for the number of metabolic risk factors, although there 
remains an ongoing discussion about the direct role of NASH on cardiovascular 
risk once concomitant metabolic syndrome factors are controlled for. 
 
Several studies have highlighted the link between fibrosis and outcome, whilst 
also noting that the presence of NASH did not seem to have a similar effect11,12. 
At one level this has been considered a controversial finding suggesting that the 
presence of inflammatory liver injury per se is not as important a driver of 
outcomes than the subsequent development of liver fibrosis. However, the 
presence of NASH, and ballooning in particular, is the hallmark of liver injury 
which in the presence of concomitant factors such as steatosis is a recognised 
driver of liver fibrosis. Without being too dogmatic this is the accepted paradigm 
by which liver injury results in fibrosis irrespective of the nature of liver damage, 
although caveats here may include the direct fibrogenic effect of certain fat 
moieties including free cholesterol. Accepting that the diagnosis/mis-diagnosis 
of NASH on liver biopsy occurs frequently14 and that this more so than fibrosis is 
a dynamic entity it is still likely that NASH is a principal driver of progression in 
such patients. Moreover, there are likely to be different fibrogenic 
susceptibilities to the development of fibrosis in response to a similar amount of 
inflammatory liver injury, thus the presence of NASH is one risk factor amongst 
others that determines the likelihood of liver fibrosis and hence clinical 
outcomes15.  
 
NAFLD in primary care 
 
In the absence of population screening, the diagnosis of NAFLD in primary care is 
usually triggered by the incidental diagnosis of abnormal liver blood tests or 
steatosis on an imaging modality performed for a separate indication. Liver 
blood tests are often requested in primary care when there is general clinical 
uncertainty as opposed to a specific query about liver disease, and thus, primary 
care physicians are often confronted with abnormal liver blood tests without any 
prior clinical clues. Further investigation of the underlying aetiology and severity 
is often driven by the magnitude of the liver blood test abnormality, which whilst 
appropriate when referring to markers of liver synthetic function is not so when 
it relates to liver enzymes. Significant liver disease can exist in the setting of 
normal or minimally abnormal liver enzymes and thus unless there is an obvious 
transient cause such as sepsis or concomitant time-limited drug prescription the 
focus should turn to the underlying cause.  
 Analysis of causation of abnormal liver blood tests in primary care indicates that 
most are caused by NAFLD or alcohol excess with a significant proportion having 
no discernible aetiology. Whilst the latter may be caused by transient illnesses 
they may also be a reflection of under-reported alcohol consumption or NAFLD 
that is not captured by ultrasonography16. In a primary care cohort of over 1,000 
patients with incidentally diagnosed abnormal liver tests, NAFLD was the 
underlying abnormality in 26% of cases, while the cause was not identified in 
45% of cases16. For patients with NAFLD there has been an ad hoc approach to 
referral resulting in cases of advanced liver disease being over-looked and 
patients with minimal disease being referred to secondary care. A systematic 
response to abnormal liver blood tests is required to standardize the approach 
for such patients17. This should include testing for viral hepatitis B and C, testing 
for autoimmune liver disease, simultaneous serum ferritin and transferrin 
saturation, a1-antithrypsin levels, serum ceruloplasmin in patients younger than 
40 years, an abdominal ultrasound and a detailed history of alcohol use and 
concomitant medication. 
 
Screening for NAFLD in primary care  
 
Although screening for NAFLD in unselected populations is not warranted, case-
finding in groups deemed at high risk of having the condition remains a 
contentious issue with conflicting guidance from the major learned societies and 
commissioning bodies1,2,17,18.  These reflect the paucity of data on disease 
progression and long-term outcomes in unselected population, the lack of an 
optimal screening test and the lack of effective disease-specific therapies that all 
hinder cost-effectiveness analyses.  
 
Magnetic resonance imaging (either with proton density fraction images or with 
spectroscopy) is the gold standard for the diagnosis of NAFLD in research 
settings, however due to accessibility and costs is not fit for clinical use at the 
moment. Abdominal ultrasound can only diagnose steatosis if it is in excess of 
20-30% and therefore will miss patients with NAFLD and a steatosis grade 
between 5% and 20%. Compared to blood-based tests, ultrasound has the 
benefit of direct visualization of the liver and the potential of diagnosing 
additional pathologies such as liver lesions. The Controlled Attenuation 
Parameter (CAP) of the Fibroscan can identify steatosis with a reasonable 
sensitivity and specificity; in an individual patient meta-analysis of almost 4,000 
patients, the AUROCs for the diagnosis of any degree and >33% of steatosis were 
0.82 and 0.86 respectively at cut-offs of 248 and 268 dB/m19. Notably, CAP 
values were influenced by the aetiology of liver disease and the presence of 
diabetes19. There are no standardized CAP cut-offs using the XL Fibroscan probe 
in obese patients. Serum based algorithms include the Fatty Liver Index (FLI), 
the NAFLD Liver Fat Score, the Hepatic Steatosis Index and the Steatotest20. 
Although these tests are useful for population-based studies, their utility is less 
optimal for population screening due to an unacceptably high number of false 
positive results. Overall, the sub-optimal specificity is an issue with all widely 
available methods for NAFLD screening21. 
 
The diagnosis of NASH is of more clinical relevance than the diagnosis of NAFLD, 
however it is hindered by the lack of non-invasive diagnostic methods. The 
circulating fragments of cytokeratin 18, which is an apoptotic marker, is the most 
studied biomarker, but has low sensitivity and does not correlate with 
ballooning, which is the hallmark of NASH22.  
 
The European Associations for the Study of the Liver (EASL), Diabetes (EASD) 
and Obesity (EASO) guidelines advocate case-finding for NAFLD with an 
abdominal ultrasound in individuals with obesity, type II diabetes, presence of 
the metabolic syndrome or incidentally discovered abnormal transaminases1. 
They advocate the use of ultrasound over serum-based algorithms because of the 
additional diagnostic information an ultrasound can provide. They also advocate 
a comprehensive evaluation of NAFLD-associated disease in patients with an 
incidental diagnosis of steatosis. In contrast, the American Association for the 
Study of Liver Disease (AASLD) guidelines do not recommend routine screening 
in high risk patient groups or any further investigation of incidental steatosis 
unless there is evidence of chronic liver disease or abnormal liver tests2. They do 
suggest a high index of suspicion in patients with type II diabetes, however with 
no specific recommendations for a diagnostic or monitoring approach. The 
recent British Society of Gastroenterology guidelines on abnormal liver blood 
tests also do not recommend screening for NAFLD until further evidence on cost-
effectiveness becomes available17. 
 
The National Institute for Clinical Excellence (NICE) in the UK performed a cost-
effectiveness analysis for NAFLD screening in the general population18. The base 
case for NAFLD testing was a 45-year old person with type II diabetes or 
presence of the metabolic syndrome. A variety of tests were compared for the 
diagnosis of >5% and >30% of steatosis. Screening for NAFLD was more cost-
effective than not; fatty liver index was the most cost-effective tests, followed by 
abdominal ultrasound. Due to the wide confidence intervals for the sensitivity of 
the fatty liver index that could potentially result in a high number of false 
positives, there was no recommendation for a specific test to diagnose NAFLD or 
for screening for NAFLD. A slightly different cost-effectiveness analysis was 
performed by Corey and co-authors23; this assumed a 50-year old with type II 
diabetes as the base case, and ultrasound for screening for NAFLD followed by a 
liver biopsy if this was positive. Patients diagnosed with NASH were treated with 
pioglitazone. There was an allowance of a 21% incidental diagnosis of NAFLD in 
the non-screened group. Screening was not cost-effective, which was mainly due 
to the decrement in the quality of life due to the side effects of pioglitazone.  
 
An important question is the burden of advanced liver disease that will be 
missed if patients at risk are not screened for NAFLD and subsequently for 
advanced liver fibrosis. It is well recognized that the severity of liver disease in 
NAFLD is independent of increased ALT values and indeed the entire histological 
spectrum can be seen in patients with normal ALT values24. In the Rotterdam 
Study, that included over 3,000 participants older than 45 years, 5.6% had 
probable clinically relevant fibrosis using Fibroscan, and this was strongly 
associated with steatosis and type II diabetes25. In a study from Hong Kong with 
almost 2,000 patients with type II diabetes and no history of chronic liver 
disease, increased liver stiffness measurements (indicating the presence of 
fibrosis) was found in 17.7% of patients; of the 94 patients who had a 
subsequent liver biopsy, 50% had advanced fibrosis or cirrhosis26. A UK study of 
919 patients at risk for chronic liver disease across four general practices, 
reported 25.6% and 2.9% prevalence of increased liver stiffness and confirmed 
cirrhosis in that population, with obesity, type II diabetes and alcohol misuse 
being the main risk factors27.  In a systematic review of non-invasive tests to 
stratify patients at risk of advanced liver disease in a general population setting, 
the prevalence of advanced fibrosis ranged from 0% to 2.7% depending on the 
population characteristics28. Normal liver blood tests were found in 
approximately 50% of patients with advanced fibrosis or cirrhosis.  
 
Therefore, although screening for NAFLD is not universally recommended at the 
moment, there is a possible rationale for case finding in risk groups rather than 
relying on the incidental diagnosis of abnormal liver tests or fatty liver on 
ultrasounds. Given the limitations of existing screening methods for the presence 
of NAFLD, looking directly for fibrosis could be alternatively explored. Strong 
collaboration with primary care and commissioners is important for the design 
of pathways for testing and referral, and the clinical effectiveness of such 
pathways will need to be tested in pragmatic studies29. The placebo arm of the 
ongoing randomized controlled trials will provide important data on the natural 
history of NAFLD that will decrease the uncertainty in cost-effectiveness 
models30. The advent of effective pharmacological treatments will also make case 
finding more relevant for physicians and patients31. 
 
Testing for advanced fibrosis 
 Although screening for NAFLD is currently contentious, testing for advanced 
fibrosis (F3 on the NASH CRN staging system) in patients with an established 
diagnosis of NAFLD was recommended in all recent guidelines1,2,17,18. The 
presence of advanced fibrosis is the most important factor that determines 
clinical outcomes in patients with NAFLD11,12. Although it would be desirable to 
target patients with significant fibrosis (F2 on the NASH CRN staging system) for 
testing strategies due to the higher risk of progression, this is currently not 
feasible due to the suboptimal diagnostic accuracy of existing non-invasive 
fibrosis tests for F2.  The NAFLD fibrosis score (NFS)32 and the FIB-433 are well-
validated simple non-invasive tests with a high negative likelihood ratio for the 
exclusion of advanced fibrosis. Importantly, patients with values below the 
lower-cut offs have excellent liver-related prognoses over ten years follow-up34. 
Assuming a prevalence of advanced fibrosis of less than 5% in unselected 
patients with NAFLD, their negative predictive value is more than 98%35. The 
FIB-4 consists of fewer variables and is thus simpler to calculate and incorporate 
in primary care pathways for triaging patients, and performs slightly better than 
NFS in head to head comparisons35.  These tests have dual cut-offs, a low and a 
high cut-off to exclude and diagnose the presence of advanced fibrosis 
respectively. The cut-offs of both scores need to be adjusted for people older 
than 65 years to account for the inappropriate weighting of age in the algorithms 
above this age that leads to reduced specificity36. A proportion of patients, 
approximately 40-50%, fall into an indeterminate category between the two cut-
off values and thus require further testing37. Therefore, a two-tier testing 
strategy is required for almost half of the patients encountered in primary care 
(Figure 1). The choice of the second tier test could be either an elastography 
technique or a proprietary serum algorithm, based on local availability and 
expertise.  
 
Fibroscan is the most widely available elastography technique, with adequate 
validation in NAFLD in both European and American cohorts38,39. The XL probe 
has allowed the performance of the technique in obese patients and has largely 
addressed the challenge encountered in NAFLD with the M probe40. Less than 
5% of examinations fail or show unreliable results in the hands of experienced 
operators, as recently reported in an audit of more than 1,500 exams39. 
Alternative elastography techniques, such as Acoustic Radiation Force Impulse 
(ARFI) and Supersonic Shear Imaging have comparable results in terms of 
diagnostic accuracy41. Magnetic resonance elastography is superior to other 
elastography techniques for lesser fibrosis stages but has similar diagnostic 
accuracy for advanced fibrosis42. It is currently available only in specialist 
centres and thus not suitable for population screening. 
 
There are a number of proprietary serum tests that were developed mainly in 
cohorts of patients with chronic hepatitis C. These include Fibrotest, the 
Enhanced Liver Fibrosis (ELF) test, Hepascore and Fibrometer 35. Both the ELF 
score 43 and Fibrometer 44  were subsequently validated in patients with NAFLD.  
 
The EASL guidelines recommend the use of non-invasive fibrosis tests to rule out 
advanced fibrosis in patients with NAFLD and normal transaminases, although 
no specific non-invasive fibrosis testing algorithm is recommended; they further 
advocate direct referral to a liver specialist in patients with abnormal 
transaminases without prior non-invasive fibrosis assessment1. It should be 
noted that the above guidance refers to individuals with cardiometabolic risk 
factors only and is intended for secondary/tertiary non-hepatologist care rather 
than primary care. The AASLD guidelines state that the NFS and FIB4 are 
clinically useful tools for identifying (rather than ruling out) advanced fibrosis 
despite the unsatisfactory positive likelihood ration of these tests and also 
mention Fibroscan and MRE, however there are no recommendations for a 
stepwise approach2. The BSG guidelines recommend the use of either NFS or 
FIB4 as a first step in all patients diagnosed with NAFLD. Patients at low risk of 
advanced fibrosis are managed in primary care, while patients at high risk are 
directly referred to secondary care. Patients at indeterminate risk undergo 
second tier testing with either ELF score or an elastography technique, based on 
local availability and expertise17. This is a pragmatic approach indicating the 
need for action and further consideration, without being too prescriptive.  
 
NICE deemed that testing for advanced fibrosis was cost-effective in NAFLD, 
although controversially concluded that the use of ELF score alone was the most 
cost-effective approach18.  This was most likely due to the fact that the diagnostic 
accuracy of the ELF score imputed in the modeling was extrapolated from a 
pediatric study of 112 patients that reported a sensitivity and specificity of 100% 
and 98% respectively45. Tapper and co-authors compared the cost-effectiveness 
of the NFS versus Fibroscan versus a combination of NFS and Fibroscan versus a 
liver biopsy, and NFS alone or its combination with Fibroscan were the most 
cost-effective options, depending on the scenario used46.  Similarly, our cost 
analysis indicated that a two-tier approach with a combination of a simple non-
invasive test with either ELF or Fibroscan results in a referral rate of 10% and 
resulted in significant cost savings35. A testing strategy is summarized in Figure 
2. The diagnostic accuracy of the most commonly used non-invasive fibrosis tests 
is summarized in Table 1. 
 
There is therefore an increasing realization that non-invasive testing for 
advanced fibrosis is required in patients with NAFLD and that it should be even 
extended to patients at risk of NAFLD even if a firm diagnosis is not present47. 
The latter has several potential benefits, as it would overcome the suboptimal 
specificity of diagnostic tests for steatosis, it would increase testing uptake by 
simplifying current algorithms and would increase awareness and shift the focus 
of physicians to a clinically meaningful diagnosis. 
Patients should be re-tested after 3-5 years to capture disease progression or 
potential false negatives of the initial testing episode. 
 
Management in primary care 
The main focus of NAFLD management in primary care should be the treatment 
of the metabolic comorbidities in order to reduce the cardiovascular risk, which 
will also prevent the future development of NASH and fibrosis (Table 2). Indeed, 
primary care physicians are much better equipped to address these risks than 
hepatologists in secondary care. Lifestyle interventions with diet and exercise 
are a key first step for all such patients. Weight loss of 10% was, in one study, 
associated with resolution of NASH and improvement of fibrosis in 90% and 
45% of patients respectively48. Bariatric surgery is an effective option in selected 
patients that fulfill certain obesity and/or comorbidity criteria49. Moreover, 
regular exercise reduces visceral and hepatic effect even in the absence of weigh 
loss50.  
Regarding pharmacotherapy, certain drugs could be preferentially considered 
for the treatment of metabolic comorbidities, due to a suggested benefit in 
NAFLD. Most of the data presented, with the exception of pioglitazone, are from 
observational or pilot studies and will need to be verified in adequately powered 
randomized controlled trials.  In a nationwide case-control study from Taiwan, 
metformin was associated with a reduced risk of hepatocellular carcinoma (HCC) 
in diabetic patients and is currently recommended as first line treatment for type 
II diabetes51. Pioglitazone has positive effects in liver histology and is a 
reasonable choice for add-on treatment in some patients without relevant 
contraindications52. Liraglutide results in weight loss and improved histology in 
patients with NAFLD as shown in a proof of concept randomized controlled 
trial53. Angiotensin II blockers may have anti-fibrotic effects and could be the 
first line treatment for hypertension54. The overall cardiovascular risk should be 
calculated in all patients using the appropriate tools (such as the QRISK2 score) 
and statins should be initiated if required. There is an unfounded perception of 
increased risk of hepatotoxicity from statins in patients with abnormal 
transaminases amongst non-liver specialists, which results in patients being 
potentially denied an essential medication. A post-hoc analysis of 437 patients 
with moderately elevated transaminases most likely due to NAFLD that 
participated in the GREACE study, demonstrated that statin treatment was safe 
and could improve transaminases and reduce cardiovascular morbidity55. 
Moreover, individuals with elevated baseline transaminases are not at higher 
risk for hepatotoxicity56. 
 
Conclusions 
The growing burden of obesity is a deeply concerning public health issue and has 
resulted in a global prevalence of NAFLD in excess of 25%57. Primary care has an 
important role in preventing the development and progression of NAFLD and 
screening patients at risk for chronic liver disease with referral to secondary 
care as required. The vast majority of patients will remain in primary care and 
therefore a focus on the active management of cardiovascular risk factors is 
essential. There is an urgent need for an integrated management plan between 
primary and secondary care, with robust pathways for testing for advanced 
fibrosis and subsequent referrals. Currently, the lack of such widespread 
pathways results in ad hoc referral strategies that potentially miss a significant 
proportion of the population at risk 58,59. The deployment of community 
hepatologists and specialist nurses might help in educating general physicians 
and raising awareness. Research is required on the need for screening for NAFLD 
and also the best pathway to screen for advanced fibrosis.  
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Table 1. Summary of most widely available non-invasive fibrosis tests for 
advanced fibrosis (NASH CRN stage 3) in patients with non-alcoholic fatty liver 
disease (NAFLD).  
 
Test Components Cut-off Sensitivity  Specificity NPV  
NFS Age, BMI, T2DM, 




0.80 0.66 0.98 
FIB4 AST, ALT, age, PLT 1.3, 
2.67 
0.84 0.74 0.98 
ELF  Hyaluronic acid, 
PIIINP, TIMP-1 
10.3 0.80 0.90 0.99 
Fibrotest A2 macroglobulin, 
haptoglobin, apo-A1, 
bilirubin, GGT, g 
globulin 
0.3, 0.7 0.88 0.73 0.99 
Fibroscan Imaging modality 8.7-9.8 
KPa 
0.82 0.82 0.99 
ARFI Imaging modality 1.2-1.3 
m/s 
0.81 0.78 0.99 
 
The negative predictive value is based on a prevalence of advanced fibrosis of 
5%. The diagnostic accuracy data are derived from Crossan35. 
 
Abbreviations: NPV: Negative Predictive Value, NFS: NAFLD Fibrosis Score, 
T2DM: Type II Diabetes Mellitus, PIIINP: Amino-terminal propeptide of type III 
collagen, TIMP-1: Tissue Inhibitor of Matrix Metalloproteinase-1, PLT: platelets, 
ELF: Enhanced Liver Fibrosis test, apo-A1: apolopoprotein A1, GGT: gamma 
glutamyltranspeptide, ARFI: Acoustic Radiation Force Impulse 
 








Obesity  Lifestyle changes, 
diet, exercise. 
Bariatric surgery 
in selected cases. 












T2DM 1. Metformin 
2. Pioglitazone 
3. Liraglutide 
HBA1c<6.5% 1. Associated with 
reduced incidence of 
HCC 
2. Resolution of 
NASH 





















Abbreviations: NASH: non-alcoholic steatohepatitis, ACE: angiotensin converting 
enzyme, T2DM: Type II Diabetes Mellitus; HBA1C: glycated hemoglobin  
Figure 1.  A general concept of the interface between primary and secondary 
care, with decision-making based on the stage of fibrosis. Although ideally 
patients with significant fibrosis (F2) should be followed in secondary care due 
to higher risk of progression, this is not feasible due to lack of available tools for 
detection of F2  and advanced fibrosis (F3) is targeted instead. 
Figure 2.  An algorithm of two-step testing for advanced fibrosis in primary care. 
Percentages that appear in the figure are based on a prevalence of advanced 
fibrosis of 5% and the diagnostic accuracy of non-invasive tests as outlined in 
Table 1. 
